A Phase 1 Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of APN1125 in Healthy Normal Subjects

Trial Profile

A Phase 1 Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of APN1125 in Healthy Normal Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Apr 2016

At a glance

  • Drugs APN 1125 (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions
  • Sponsors CoMentis
  • Most Recent Events

    • 07 Apr 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 25 Mar 2016 Planned End Date changed from 1 Apr 2016 to 1 Jul 2016 as reported by ClinicalTrials.gov.
    • 25 Mar 2016 Planned primary completion date changed from 1 Jan 2016 to 1 Jun 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top